TaiwanJ To Progress Liver Drug JKB-122 In AIH After Good Phase II Data
Executive Summary
Taiwanese speciality pharma TaiwanJ said its Phase II orphan drug designation study of investigational therapy JKB-122 in autoimmune hepatitis met both the primary and secondary endpoints.